

Studies of Nondefective Adenovirus 2-Simian Virus 40 Hybrid Viruses

VIII. Association of Simian Virus 40 Transplantation Antigen with a Specific Region of the Early Viral Genome

ANDREW M. LEWIS, JR., AND WALLACE P. ROWE

Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20014

Received for publication 25 June 1973

Two of the five nondefective adenovirus 2 (Ad2)-simian virus 40 (SV40) hybrids induce SV40 transplantation resistance in immunized hamsters. These two hybrids, Ad2⁺ND₂ and Ad2⁺ND₄, contain 32 and 43% of the SV40 genome, respectively. The pattern of induction of SV40 transplantation antigen (TSTA) by the various hybrids differentiates TSTA from both SV40 U and T antigens. Since the SV40 RNA induced by both these hybrids is early SV40 RNA, these findings confirm that TSTA is an early SV40 function. By combining available data on SV40 antigen induction by these hybrids with electron microscopy heteroduplex mapping studies, the DNA segment responsible for the induction of SV40 TSTA can be inferred to lie in the region between 0.17 and 0.43 SV40 units from the site on the SV40 chromosome cleaved by *E. coli* R₁ restriction endonuclease.

The presence of a virus-specific transplantation antigen (TSTA) in simian virus 40 (SV40)-induced tumors and transformed cells has been well documented (5, 7, 8, 15, 17). This antigen is detected by the resistance in SV40-immune animals to tumor induction by SV40 or SV40-transformed cells. It has been distinguished from SV40 T antigen by the lack of serologically detectable T antibody in the sera of SV40-immune hamsters who resist the development of tumors (3) and by the sensitivity of the TSTA antigen to freezing and thawing (4). By cytotoxicity assays, SV40 TSTA has been found on the surface of SV40-transformed cells, and immunization of animals with membrane-rich subcellular fractions from such cells inhibits the development of tumors after challenge with viable cells, whereas immunization with nuclear or soluble cytoplasmic fractions affords no protection (34). In lytically infected cells, the development of SV40 TSTA was not affected by inhibitors of DNA synthesis or low levels of actinomycin D, but was inhibited by inhibitors of protein synthesis and by a concentration of actinomycin D that inhibits early and late viral functions (6). Thus, TSTA appears to be an early SV40 function which produces viral-specific alterations on the surface of transformed or lytically infected cells.

To begin to elucidate the mechanism by

which SV40 induces specific changes on the cell surface, it would be useful to define further the TSTA function by associating it with a specific region of the viral genome. Rapp et al. (28, 30) initially demonstrated that a subunit of the SV40 genome contained in the defective adenovirus 7 (Ad7)-SV40 hybrid, E46⁺, induced SV40 TSTA. The segment of SV40 DNA within the genome of the Ad7-SV40 hybrid particles seems to induce only early SV40-specific antigens and early SV40 RNA (12, 23, 26, 29, 32). However, this SV40 DNA segment appears to consist of 70% of the SV40 chromosome (14), which is about twice the suspected size of the early region of the SV40 genome.

Recently, a group of five nondefective Ad2-SV40 hybrid viruses have been isolated (20, 21). Designated Ad2⁺ND₁ through Ad2⁺ND₅, these agents induce only early SV40 antigens and/or early SV40-specific RNA (19, 21) and contain Ad2 DNA covalently linked to SV40 DNA segments which comprise up to 43% of the SV40 genome (see Fig. 1; references 10 and 13). During the characterization of the nondefective Ad2-SV40 hybrids, we were interested in determining whether any of these agents were capable of inducing SV40-specific TSTA.

The purpose of this report is to characterize further SV40 TSTA by associating it with the SV40 DNA segment contained in the Ad2⁺ND₂

hybrid, and to present the experimental data which were used to order the known antigen-inducing regions in the early portion of the SV40 genome (13, 25).

MATERIALS AND METHODS

Viruses. The isolation of the nondefective Ad2-SV40 hybrid viruses from the nondefective B55 hybrid pool has been described (20, 21). Ad2⁺ND₁, Ad2⁺ND₂, Ad2⁺ND₃, and Ad2⁺ND₄ were propagated in human embryonic kidney (HEK) cells, while Ad2⁺ND₄ was grown in African green monkey kidney cells (AGMK). All virus stocks used in these experiments represented the third tissue culture passage after plaque isolation (B55 and Ad2⁺ND₄) or plaque purification (Ad2⁺ND₁, Ad2⁺ND₃, and Ad2⁺ND₅). Infectivity titers ranged from 3×10^8 to 1×10^9 PFU/ml by plaque titrations in HEK cells.

The prototype strain of Ad2 (strain Ad6) has been maintained by serial passage in HEK cells. The pool used in these experiments titered 6.9×10^8 PFU/ml in HEK cells.

SV40 strain 777 (2) has been maintained in our laboratory by serial, low-multiplicity ($<10^{-5}$ PFU/cell) passage in the BSC-1 line of AGMK cells (11). The three virus pools used in these experiments contained infectious virions in concentrations of 2×10^9 , 3×10^9 , and 4.4×10^9 PFU/ml in AGMK cells.

All virus pools were demonstrated to be free of mycoplasma by anaerobic culture on Hayflick medium (9), and all pools of Ad2 and hybrid viruses were shown to be free of adeno-associated viruses types 1 to 4 by complement fixation testing.

Cell lines. The SV40-transformed cell line (THK-1₁) used to challenge vaccinated hamsters was obtained from a subcutaneous tumor induced in weanling NIH hamsters by the THK-1 line (1) of SV40-transformed hamster kidney cells. After the fifth tissue culture passage, cells were concentrated by centrifugation ($500 \times g$ for 10 min); suspended in Eagle minimal essential medium containing 200 mmol of glutamine, 250 U of penicillin, and 250 μ g of streptomycin per ml (EMEM), supplemented with 8% dimethylsulfoxide and 25% fetal bovine serum (FBS); and stored in sealed ampoules (50×10^6 cells/ml) in liquid nitrogen. Shortly before the hamsters were to be injected, the cells were rapidly thawed at 37 C and diluted in EMEM with 10% FBS. All THK-1₁ cells used for these experiments came from the same frozen lot.

Transplantation rejection tests. The techniques used to immunize and challenge hamsters were similar to those described by Rapp et al. (30). Groups (5-10 animals per group) of 3- to 4-week-old weanling hamsters were injected intraperitoneally at weekly intervals with 1 ml of virus stock for a total of three injections. Individual injections contained 10^7 to 10^8 PFU of SV40 per ml or 10^8 to 10^9 PFU of nondefective Ad2-SV40 hybrid viruses per ml. One week after the final injection the hamsters were challenged by subcutaneous injection of $10^{0.5}$, $10^{1.0}$, and $10^{1.5}$ tumor-producing doses (TPD₅₀) of THK-1₁ cells. Animals were examined weekly for the presence of tumors. The experiments were terminated 3 months after challenge.

RESULTS

Design of the animal experiments and titration of SV40-transformed THK-1₁ cells in hamsters. After initial tests to establish the optimum number of SV40-transformed cells to be used for the challenge, each experiment included nonimmune hamsters, hamsters immunized with a virus known to induce SV40 TSTA (either SV40 or a nondefective hybrid), and two to four groups of hamsters immunized with the agents to be tested for their ability to induce SV40 TSTA. With the exception of the B55 hybrid pool, all nondefective hybrids were tested in two separate experiments. The results of these experiments are presented in Tables 1 and 2.

The data in Table 1 indicate that approximately 3,000 THK-1₁ cells were required to produce tumors in 50% of the hamsters. Immunization with SV40 increased the TPD₅₀ (the number of THK-1₁ cells required to produce tumors in 50% of the hamsters) 30-fold.

These data were confirmed in another experiment by a 50-fold increase in resistance obtained by immunizing hamsters with the strain of SV40 isolated from the Ad2⁺ LEY hybrid (Table 2) (22).

Induction of SV40-specific TSTA by nondefective Ad2-SV40 hybrids. From the data in Table 2 it is apparent that immunization with the two nondefective Ad2-SV40 hybrids con-

TABLE 1. Effects of SV40 immunization on the induction of tumors by THK-1₁ cells

| Immunizing virus | No. cells inoculated per hamster (log 10) | No. tumor-bearing hamsters/no. inoculated hamsters | | | TPD ₅₀ (log 10) ^a | Resistance ^b |
|-------------------|---|--|--------|--------|---|-------------------------|
| | | Expt 1 | Expt 2 | Expt 3 | | |
| None | 2.0 | 0/5 | | | 3.5 | |
| | 3.0 | 0/5 | | | | |
| | 4.0 | 5/5 | 10/10 | 9/10 | | |
| | 4.5 | | 10/10 | 9/10 | | |
| | 5.0 | 5/5 | 10/10 | 10/10 | | |
| SV40 ^c | 2.0 | 0/5 | | | 5.0 | 30 |
| | 3.0 | 0/5 | | | | |
| | 4.0 | 0/5 | 1/10 | 0/10 | | |
| | 4.5 | | 6/10 | 1/10 | | |
| | 5.0 | 3/5 | 9/10 | 2/10 | | |

^a To calculate the TPD₅₀, the data in experiments 1, 2, and 3 were pooled and evaluated by the method of Reed and Muench (31).

^b Resistance = TPD₅₀ in immunized hamsters/TPD₅₀ in nonimmunized hamsters.

^c Immunizing dose of SV40: Expt 1, 2×10^7 PFU/injection; Expt 2, 3×10^7 PFU/injection; Expt 3, 4.4×10^8 PFU/injection.

TABLE 2. Effects of immunization with nondefective Ad2-SV40 hybrids on the induction of tumors by THK-1, cells

| Immunizing virus | Size of SV40 DNA segment within each hybrid ^a | No. cells inoculated per hamster (log 10) | No. tumor-bearing hamsters/no. inoculated hamsters | | TPD ₅₀ (log 10) | | Resistance ^b | |
|----------------------------------|--|---|--|--------|----------------------------|--------|-------------------------|--------|
| | | | Expt 1 | Expt 2 | Expt 1 | Expt 2 | Expt 1 | Expt 2 |
| Ad2 ⁺ ND ₁ | 0.18 | 4.0 | 9/10 | 10/10 | <3.8 | <3.8 | <2 | <2 |
| | | 4.5 | 10/10 | 9/10 | | | | |
| | | 5.0 | 10/10 | 8/8 | | | | |
| Ad2 ⁺ ND ₂ | 0.32 | 4.0 | 0/10 | 1/10 | 4.6 | 4.8 | 13 | 20 |
| | | 4.5 | 5/10 | 1/10 | | | | |
| | | 5.0 | 7/10 | 7/10 | | | | |
| Ad2 ⁺ ND ₃ | 0.06 | 4.0 | 10/10 | 10/10 | <3.7 | <3.7 | <1.6 | <1.6 |
| | | 4.5 | 9/10 | 10/10 | | | | |
| | | 5.0 | 10/10 | 10/10 | | | | |
| Ad2 ⁺ ND ₄ | 0.43 | 4.0 | 1/10 | 0/10 | 4.8 | 4.8 | 20 | 20 |
| | | 4.5 | 1/10 | 1/10 | | | | |
| | | 5.0 | 8/10 | 7/10 | | | | |
| Ad2 ⁺ ND ₅ | 0.28 | 4.0 | 10/10 | 10/10 | <3.7 | <3.7 | <1.6 | <1.6 |
| | | 4.5 | 10/10 | 10/10 | | | | |
| | | 5.0 | 10/10 | 10/10 | | | | |
| B 55 | — | 4.0 | 2/10 | | ≥5.1 | | ≥40 | |
| | | 4.5 | 1/10 | | | | | |
| | | 5.0 | 1/10 | | | | | |
| Ad2 | | 4.0 | 8/10 | | <3.8 | | <2 | |
| | | 4.5 | 10/10 | | | | | |
| | | 5.0 | 10/10 | | | | | |
| SV40/LEY ^d | | 4.0 | 0/10 | | 5.2 | | 50 | |
| | | 4.5 | 0/10 | | | | | |
| | | 5.0 | 1/10 | | | | | |

^a Expressed as fraction of 1 SV40 genome equivalent (unit) as determined by electron microscopy (13).

^b Resistance = TPD₅₀ in immunized hamsters/TPD₅₀ in nonimmunized hamsters = 10^{3.5}.

^c The size of the SV40 DNA segment within the genome of the hybrid virions in this pool has not been determined.

^d Added as an additional control, SV40/LEY is the SV40 isolated from the Ad2⁺ LEY hybrid (22). The pool used in this experiment was prepared in primary AGMK cells and contained 3 × 10⁸ PFU of infectious SV40 virions per ml.




FIG. 1. Location of SV40 DNA segments and functions in the nondefective hybrid genomes and the approximate location of these regions in the SV40 chromosome (adapted from Kelly and Lewis, and Morrow et al., 13, 24, 25). The placement of U, TSTA, and T along the R₁ linear should not be interpreted as the precise location of these antigen-inducing regions (see Discussion).

taining the largest SV40 DNA segments (Ad2⁺ND₂ and Ad2⁺ND₄) increased the resistance of hamsters to tumor induction by THK-1, cells by 13- to 20-fold.

In a single test, immunization with the B55 hybrid pool, which is biologically indistinguishable from Ad2⁺ND₄ and from which all the nondefective Ad2-SV40 hybrids were derived, produced a 40-fold increase in the TPD₅₀.

Neither nonhybrid Ad2, Ad2⁺ND₃ (containing 0.06 SV40 units [for a definition of SV40 unit see footnote b, Table 2]), Ad2⁺ND₁ (0.18 SV40 units), nor Ad2⁺ND₅ (0.28 SV40 units) induced detectable transplantation resistance in these experiments.

DISCUSSION

The experiments described in this paper correlate the size of the SV40 DNA segments contained within the nondefective hybrid genomes with the ability of these viruses to induce SV40 TSTA. Since SV40 U antigen is induced by the smaller SV40 DNA segment in the Ad2⁺ND₁ genome and SV40 T antigen induction requires an additional segment of SV40 DNA present in the Ad2⁺ND₄ genome, the induction of SV40 TSTA by the SV40 DNA segment within Ad2⁺ND₂ differentiates this antigen from SV40 U and T antigens.

Girardi and Defendi (6) demonstrated that the development of SV40 TSTA in lytically infected cells was unaffected by inhibitors of DNA synthesis and concluded that this antigen represented an early SV40 function. In support of this conclusion, we point out that more than 90% of the SV40 RNA sequences present at 24 h in Ad2⁺ND₂- and Ad2⁺ND₄-infected Vero cells are identical (by nucleic acid hybridization competition) to SV40 RNA made early during the lytic cycle (19). Furthermore, Khoury et al. (submitted for publication) have shown that, like early RNA from SV40-infected cells, the SV40 RNA present at 24 h in Ad2⁺ND₂- and Ad2⁺ND₄-infected Vero cells reacts only with the minus or E strand of SV40 DNA (16, 33). Since it is likely that, in the inoculated hamsters, transcription of the SV40 DNA segments in the nondefective Ad2-SV40 hybrids is the same as transcription of these segments in lytically infected Vero cells, these data indicate that SV40 TSTA is induced by the SV40 DNA sequences on the minus SV40 strand and is an early SV40 function.

The findings presented in this paper have been used to order the known SV40 early antigen-inducing regions within the SV40 genome and to relate these segments to the R₁ site on the SV40 genome (Fig. 1; references 13, 24,

and 25). Combining the data on SV40 antigen induction by the nondefective hybrid viruses with the electron microscopy heteroduplex mapping studies, it would appear that SV40 DNA lying between the termination site of the Ad2⁺ND₁-SV40 DNA segment at 0.29 SV40 units from the R₁ site and the termination site for the Ad2⁺ND₂-SV40 DNA segment at 0.43 SV40 units is required for TSTA induction. However, these data do not fix the precise location of the TSTA-inducing region of the SV40 genome. With reference to the orientation of the diagram in Fig. 1, the right-hand end of the TSTA-inducing DNA segment must lie between 0.29 and 0.43, while the left-hand end could extend to the left of 0.29 into the Ad2⁺ND₁-SV40 DNA segment. Moreover, Patch et al. (27; and manuscript submitted for publication) have shown that all of the nondefective hybrid SV40 DNA segments contain late as well as early SV40 DNA. These data suggest that one or more late templates may exist within the early SV40 region as well as on either side. The exact manner in which these late SV40 DNA sequences interdigitate with the early SV40 DNA sequences in this region of the SV40 genome is not yet known. Thus, more detailed knowledge of the topography of the early region of the SV40 genome will be required to identify precisely the regions which induce the early SV40 antigens.

It should be noted that the Ad2⁺ND₅ hybrid, which contains almost as long an SV40 DNA segment as Ad2⁺ND₂, but fails to induce serologically detectable SV40 antigens, also failed to induce detectable SV40 TSTA. This could indicate that the right-hand end of the TSTA-inducing region lies to the right of 0.39 SV40 units; more likely, Ad2⁺ND₅ fails to induce TSTA for the same unknown reason (perhaps a frameshift) that it fails to induce SV40 U antigen.

ACKNOWLEDGMENT

We acknowledge the excellent technical assistance of John W. Jones.

LITERATURE CITED

1. Black, P. H., and W. P. Rowe. 1963. An analysis of SV40 induced transformation of hamster kidney tissue *in vitro*. I. General characteristics. Proc. Nat. Acad. Sci. U.S.A. 50:606-613.
2. Black, P. H., and W. P. Rowe. 1964. Viral studies of SV40 tumorigenesis in hamsters. J. Nat. Cancer Inst. 32:253-265.
3. Black, P. H., W. P. Rowe, H. C. Turner, and R. J. Huebner. 1963. A specific complement-fixing antigen present in SV40 tumor and transformed cells. Proc. Nat. Acad. Sci. U.S.A. 50:1148-1156.
4. Coggin, J. H., V. M. Larson, and M. R. Hilleman. 1966.

- Prevention of SV40 virus tumorigenesis by irradiated, disrupted, and iododeoxyuridine treated tumor cell antigens. *Proc. Soc. Exp. Biol. Med.* **124**:774-784.
5. Defendi, V. 1963. Effect of SV40 virus immunization on growth of transplantable SV40 and polyoma virus tumors in hamsters. *Proc. Soc. Exp. Biol. Med.* **113**:12-15.
 6. Girardi, A. J., and V. Defendi. 1970. Induction of SV40 transplantation antigen (TrAg) during the lytic cycle. *Virology* **42**:688-698.
 7. Goldner, H., A. J. Girardi, V. M. Larson, and M. R. Hilleman. 1963. Interruption of SV40 virus tumorigenesis using irradiated homologous tumor antigen. *Proc. Soc. Exp. Biol. Med.* **117**:851-857.
 8. Habel, K., and B. E. Eddy. 1963. Specificity of resistance to tumor challenge of polyoma and SV40 virus-immune hamsters. *Proc. Soc. Exp. Biol. Med.* **113**:1-4.
 9. Hayflick, L. 1965. Tissue culture and mycoplasma. *Tex. Rep. Biol. Med.* **23**:285-303.
 10. Henry, P. H., L. E. Schnipper, R. J. Samaha, C. S. Crumpacker, A. M. Lewis, Jr., and A. S. Levine. 1973. Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VI. Characterization of the deoxyribonucleic acid from five nondefective hybrid viruses. *J. Virol.* **11**:665-671.
 11. Hopps, H., B. C. Bernheim, A. Nisalak, J. H. Tjio, and J. E. Smadel. 1963. Biologic characteristics of a continuous kidney cell line derived from the African green monkey. *J. Immunol.* **91**:416-424.
 12. Huebner, R. J., R. M. Chanock, B. A. Rubin, and M. J. Casey. 1964. Induction of adenovirus type 7 of tumors in hamsters having the antigenic characteristics of SV40 virus. *Proc. Nat. Acad. Sci. U.S.A.* **52**:1333-1340.
 13. Kelly, T. J., Jr., and A. M. Lewis, Jr. 1973. Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome. *J. Virol.* **12**:643-652.
 14. Kelly, T. J., Jr., and J. A. Rose. 1971. Simian virus 40 intergration site in an adenovirus 7-simian virus 40 hybrid DNA molecule. *Proc. Nat. Acad. Sci. U.S.A.* **68**:1037-1041.
 15. Khera, K. S., A. Ashkenazi, F. Rapp, and J. L. Melnick. 1963. Immunity in hamsters to cells transformed *in vitro* and *in vivo* by SV40. *J. Immunol.* **91**:604-613.
 16. Khoury, G., and M. A. Martin. 1972. Comparison of SV40 DNA transcription *in vivo* and *in vitro*. *Nature N. Biol.* **238**:4-6.
 17. Koch, M. A., and A. B. Sabin. 1963. Specificity of virus-induced resistance to transplantation of polyoma and SV40 tumors in adult hamsters. *Proc. Soc. Exp. Biol. Med.* **113**:4-12.
 18. Levin, M. J., C. S. Crumpacker, A. M. Lewis, Jr., M. N. Oxman, P. H. Henry, and W. P. Rowe. 1971. Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. II. Relationship of adenovirus 2 deoxyribonucleic acid and simian virus 40 deoxyribonucleic acid in the Ad2·ND₁ genome. *J. Virol.* **7**:343-351.
 19. Levine, A. S., M. J. Levin, M. N. Oxman, and A. M. Lewis, Jr. 1973. Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. VII. Characterization of the simian virus 40 RNA species induced by five nondefective hybrid viruses. *J. Virol.* **11**:672-681.
 20. Lewis, A. M., Jr., M. S. Levin, W. H. Wiese, C. S. Crumpacker, and P. H. Henry. 1969. A nondefective (competent) adenovirus-SV40 hybrid isolated from the Ad₂-SV40 hybrid population. *Proc. Nat. Acad. Sci. U.S.A.* **63**:1128-1135.
 21. Lewis, A. M., Jr., A. S. Levine, C. S. Crumpacker, M. J. Levin, R. J. Samaha, and P. H. Henry. 1973. Studies of nondefective adenovirus 2-simian virus 40 hybrid viruses. V. Isolation of additional hybrids which differ in their simian virus 40-specific biological properties. *J. Virol.* **11**:655-664.
 22. Lewis, A. M., Jr., and W. P. Rowe. 1970. Isolation of two plaque variants from the adenovirus type 2-simian virus 40 hybrid population which differ in their efficiency in yielding simian virus 40. *J. Virol.* **5**:413-420.
 23. Lewis, A. M., Jr., and W. P. Rowe. 1971. Studies on nondefective adenovirus-simian virus 40 hybrid viruses. I. A newly characterized simian virus 40 antigen induced by the Ad2·ND₁ virus. *J. Virol.* **7**:189-197.
 24. Morrow, J. F., and P. Berg. 1972. Cleavage of simian virus 40 DNA at a unique site by a bacterial restriction enzyme. *Proc. Nat. Acad. Sci. U.S.A.* **69**:3365-3369.
 25. Morrow, J. F., P. Berg, T. J. Kelly, Jr., and A. M. Lewis, Jr. 1973. Mapping of simian virus 40 early functions on the viral chromosome. *J. Virol.* **12**:653-658.
 26. Oda, K., and R. Dulbecco. 1968. Regulation of transcription of the SV40 DNA in productively infected and transformed cells. *Proc. Nat. Acad. Sci. U.S.A.* **60**:525-532.
 27. Patch, C. T., A. M. Lewis, Jr., and A. S. Levine. 1972. Evidence for a transcription-control region of simian virus 40 in the adenovirus 2-simian virus 40 hybrid, Ad2·ND₁. *Proc. Nat. Acad. Sci. U.S.A.* **69**:3375-3379.
 28. Rapp, F., J. S. Butel, S. S. Tevethia, and J. L. Melnick. 1967. Comparison of ability of defective foreign genomes (PARA and MAC) carried by human adenoviruses to induce SV40 transplantation immunity. *J. Immunol.* **99**:386-391.
 29. Rapp, F., J. L. Melnick, J. S. Butel, and T. Kitahara. 1964. The incorporation of SV40 genetic material into adenovirus 7 as measured by intranuclear synthesis of SV40 tumor antigen. *Proc. Nat. Acad. Sci. U.S.A.* **52**:1348-1352.
 30. Rapp, F., S. S. Tevethia, and J. L. Melnick. 1966. Papovavirus SV40 transplantation immunity conferred by an adenovirus-SV40 hybrid. *J. Nat. Cancer Inst.* **36**:703-708.
 31. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. *Amer. J. Hyg.* **27**:493-497.
 32. Rowe, W. P., and S. G. Baum. 1964. Evidence for a possible genetic hybrid between adenovirus type 7 and SV40 viruses. *Proc. Nat. Acad. Sci. U.S.A.* **52**:1340-1347.
 33. Sambrook, J., P. A. Sharp, and W. Keller. 1972. Transcription of simian virus 40. I. Separation of the strands of SV40 DNA and hybridization of the separated strands to RNA extracted from lytically infected and transformed cells. *J. Mol. Biol.* **70**:57-71.
 34. Smith, R. W., J. Morganroth, and P. T. Mora. SV40 virus-induced tumor specific transplantation antigen in cultured mouse cells. *Nature (London)* **227**:141-145.